Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04329221
Recruitment Status : Not yet recruiting
First Posted : April 1, 2020
Last Update Posted : April 7, 2022
Sponsor:
Collaborator:
Washington University School of Medicine
Information provided by (Responsible Party):
Shadmehr Demehri, Massachusetts General Hospital

Brief Summary:
This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-fluorouracil cream as an immunotherapy for actinic keratosis in Organ Transplant Recipients (OTRs) before transplantation and determine whether it can prevent cutaneous squamous cell carcinoma (SCC) in OTRs post-transplant.

Condition or disease Intervention/treatment Phase
Cutaneous Squamous Cell Carcinoma Actinic Keratoses Skin Cancer Organ Transplant Recipients Immunotherapy Drug: Calcipotriol Only Product in Cutaneous Dose Form Drug: Vaseline Drug: Topical 5FU Phase 2

Detailed Description:
The main goal of this investigator-initiated clinical trial is to determine the efficacy of topical calcipotriol combined with 5-flourouracil (5-FU) treatment in organ transplant candidates with precancerous skin lesions called actinic keratoses (AKs) with a history of skin cancer in order to prevent squamous cell carcinoma (SCC) development after transplantation. SCC is the most common cutaneous malignancy seen after transplantation, with a 65-250 fold greater incidence in organ transplant recipients (OTRs) compared to the general population. This increased risk is due to the systemic immunosuppression caused by anti-rejection medications, which are indispensable for protecting against allograft loss. Previously, we have demonstrated the high efficacy of topical calcipotriol plus 5-FU immunotherapy for AKs on the face and scalp in significantly reducing the risk of SCC development within 3 years post-treatment in immunocompetent patients. This SCC risk reduction is accompanied by the induction of robust T cell immunity and TRM cell formation against AKs. Calcipotriol is a low calcemic vitamin D analogue that is FDA-approved for the treatment of psoriasis. Topical 5-FU is a chemotherapy that is the standard treatment for AKs. Our previous research demonstrates the synergistic impact of calcipotriol in combination with 5-FU on a robust T cell immunity against early skin carcinogenesis in immunocompetent patients. Therefore, we aim to determine the efficacy of this immunotherapy before transplantation in reducing the risk of SCC post-transplant despite the immunosuppressive medications.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: All participants, care giver and investigators measuring or analyzing the experimental data will be blinded to the interventions. Tissue samples collected will be labeled with 3-digit unique IDs and de-identified before studying in PI's lab. The study investigator will collect AK/skin samples and label them based on the study ID (e.g. "201") without compromising their blinded status. All the study records/photographs will be kept in a locked office or password-protected computer that is only accessible by the members of the research team.
Primary Purpose: Prevention
Official Title: Calcipotriol Plus 5-Flourouracil Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Estimated Study Start Date : January 1, 2023
Estimated Primary Completion Date : January 2026
Estimated Study Completion Date : January 2027

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Topical Calcipotriol ointment plus 5-Fluorouracil cream
Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
Drug: Calcipotriol Only Product in Cutaneous Dose Form
Calcipotriol (Calcipotriene) is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
Other Name: Topical Calcipotriol ointment

Drug: Topical 5FU
5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
Other Name: Topical 5-fluorouracil

Placebo Comparator: Topical vaseline plus 5-Fluorouracil 2.5% cream
Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
Drug: Vaseline
Placebo
Other Name: Petrolatum

Drug: Topical 5FU
5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
Other Name: Topical 5-fluorouracil




Primary Outcome Measures :
  1. The changes in the percentage of participants with new SCC on treated anatomical sites in OTRs [ Time Frame: Year 2 post-transplant ]
    The changes in the percentage of participants with new SCC on treated anatomical sites quantified based on participants' medical records, photographs and pathology results after transplantation in test versus control group.


Secondary Outcome Measures :
  1. The percent change in baseline number of AKs on the treated anatomical sites in OTRs. [ Time Frame: 8 weeks after treatment ]
    The percent change in baseline number of AKs on the treated anatomical sites in post-transplant OTRs quantified based on participants' medical records and photographs after transplantation in test versus control group

  2. The changes in TSLP, CD3+, CD4+ and CD8+ TRM cell infiltrates and other immune factors/cells in the AK and normal skin [ Time Frame: at one day after 6-day treatment and at one year post-transplant. ]
    The changes in TSLP, CD3+, CD4+ and CD8+ TRM cell infiltrates and other immune factors/cells in the AK and normal skin in test versus control group after treatment and transplantation compared to before treatment.

  3. The changes in immune infiltrate in any SCC that develops after treatment [ Time Frame: for up to 4 years post-transplant ]
    The changes in immune infiltrate in any SCC that develops after calcipotriol plus 5-FU versus Vaseline plus 5-FU treatment

  4. The changes in SCC prevention (SCC number) on the untreated anatomical sites (i.e., trunk and lower extremities) of OTRs [ Time Frame: at one, two and four years post-transplant. ]
    The changes in efficacy of a twice daily 6-day treatment with topical calcipotriol plus 5-FU (test) versus Vaseline plus 5-FU (control) before transplantation in preventing SCC on the untreated anatomical sites (i.e., trunk and lower extremities) of OTRs.

  5. The changes in erythema extent and intensity scores of the treated anatomical sites [ Time Frame: at one day after the completion of a 6-day treatment. ]
    The changes in erythema extent and intensity scores of the treated anatomical sites after treatment in test versus control group. Treated skin will be evaluated for any sign of irritation including erythema, crusting or ulceration using a clinical erythema scale.

  6. Number of Participants with Treatment Related Adverse Events [ Time Frame: From the start of treatment until 30 days after the end of treatment, up to 2 months ]
    Adverse events will be assessed including any local skin reactions like itching and rash.

  7. Number of participants with any proven rejection of the graft in OTRs [ Time Frame: From the start of treatment until 30 days after the end of treatment ]
    Number of participants with any biopsy proven acute rejection of the graft after treatment with calcipotriol plus 5-FU compared to test group

  8. The changes in response to treatment (AK and SCC number) between treated anatomical sites [ Time Frame: at one day after treatment and one year after transplantation. ]
    The changes in response to topical calcipotriol plus 5-FU versus Vaseline plus 5-FU between treated anatomical sites



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Solid organ transplant candidates with AKs and a history of non-melanoma skin cancer. The target population includes the patients who are undergoing kidney, lung, liver and heart transplantations.
  • Presence of four to fifteen clinically typical, visible, and discrete AKs in 25 cm2 on any of the four anatomical sites: scalp, face, right upper extremity and left upper extremity.
  • The period between the first visit and transplantation is minimum 4 weeks and maximum 12 months.
  • Age of at least 18 years
  • Ability and willingness of the patient to participate in the study (Informed consent will be obtained)

Exclusion Criteria:

  • Treatment area is within 5 cm of an incompletely healed wound or a suspected basal cell or squamous cell carcinoma.
  • Treatment area contained hypertrophic and hyperkeratotic lesions, cutaneous horns, or lesions that had not responded to repeated cryotherapy.
  • Patients with history of hypercalcemia or vitamin D toxicity.
  • Female participants must be either of non-reproductive potential (i.e., post-menopausal by history of age > 50 years old and no menses for >1 year without an alternative medical cause; OR history of hysterectomy, history of bilateral tubal ligation, or history of bilateral oophorectomy) OR must have a negative serum pregnancy test within 7 days prior to study registration.
  • Patients with DPD (Dihydropyrimidine Dehydrogenase) deficiency (due to their higher risk of 5-FU toxicity).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04329221


Contacts
Layout table for location contacts
Contact: Shadmehr Demehri, MD 617-643-6436 sdemehri1@mgh.harvard.edu
Contact: Marjan Azin, MD 617-724-7897 mazin@mgh.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02215
United States, Missouri
Barnes-Jewish Hospital
Saint Louis, Missouri, United States, 63108
Contact: Milan J Anadkat, MD    314-362-2643    manadkat@dom.wustl.edu   
Sponsors and Collaborators
Massachusetts General Hospital
Washington University School of Medicine
Investigators
Layout table for investigator information
Principal Investigator: Shadmehr Demehri, MD/PHD Massachusetts General Hospital
Publications:
Layout table for additonal information
Responsible Party: Shadmehr Demehri, MD, PHD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT04329221    
Other Study ID Numbers: 2019P003401
First Posted: April 1, 2020    Key Record Dates
Last Update Posted: April 7, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Shadmehr Demehri, Massachusetts General Hospital:
Calcipotriol ointment
5-FU cream
Squamous Cell Carcinoma
Actinic Keratoses
Organ Transplant Recipients
Prevention
Immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Keratosis, Actinic
Skin Neoplasms
Keratosis
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Skin Diseases
Precancerous Conditions
Neoplasms by Site
Calcitriol
Fluorouracil
Calcipotriene
Petrolatum
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Dermatologic Agents
Calcium-Regulating Hormones and Agents
Calcium Channel Agonists
Membrane Transport Modulators
Vasoconstrictor Agents
Vitamins
Micronutrients